A Randomized, Open-Label, Two-Arm Study of Neratinib (HKI-272) Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer

Trial Profile

A Randomized, Open-Label, Two-Arm Study of Neratinib (HKI-272) Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Neratinib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NEFERTT
  • Sponsors Puma Biotechnology; Wyeth Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2016 Puma Biotechnology media release, results from this trial published in JAMA Oncology.
    • 14 Apr 2016 Results published in the Media Release
    • 02 Jun 2015 Efficacy and tolerability results (n=479 ITT) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top